Novo Nordisk has picked second RNA drug candidate for USD 358m collaboration
Novo Nordisk and US-based Dicerna, which in 2019 announced their million-dollar partnership to the develop potential RNA drugs, have chosen their second candidate. According to the Danish pharmaceutical company, the choice was made during the first half of the year.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
The multi-million-dollar collaboration between Novo Nordisk and US-based Dicerna, dealing with the development of new potential RNA drugs, has seen its second candidate, the former tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
